comparemela.com

Latest Breaking News On - B cell precursor acute lymphoblastic leukemia - Page 1 : comparemela.com

FDA Grants Full Approval to Blinatumomab for MRD+ B-cell Precursor ALL

The FDA has granted regular approval to blinatumomab (Blincyto) for the treatment of adult and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease of at least 0.1%

United statesDavidm reeseAccessed juneMinimal residual diseaseB cell precursor acute lymphoblastic leukemiaBlood cancerFda approvalRegular approvalMlb all

FDA Grants Full Approval for Blincyto to Treat B-ALL

The full approval is based on data showing that 80% of patients with B-ALL experienced a complete MRD response.

United statesDavidm reeseElias jabbourDrug administrationUniversity of texas md anderson cancer centerCancer centerB cell precursor acute lymphoblastic leukemiaMlb allAcute lymphoblastic leukemiaB cell precursor acute lymphoblastic leukemia

OSE Immunotherapeutics Reports 2021 Financial Results: Major Progress on its Clinical Programs and a Solid Cash Position to Support its Activities

Shared positive final Phase 3 results for Tedopi in non-small cell lung cancer (NSCLC) patients in secondary resistance after failure with second-line checkpoint inhibitor treatment. Received

United statesFrance generalAlexandre lebeautGuillaume van renterghem lifesciThomas guillotAlexis peyrolesElise chiffoleauDominique costantiniFlorence portejoieDarren oplandEuropean patent officeNantes university at hospitalBoehringer ingelheimAudit committeeAmerican society of hematologyTrademark office

OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia

At the 2021 American Society of Hematology (ASH) Annual Meeting Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) presented the first preclinical data on

United statesSachsen anhaltDenis scheweGuillaume van renterghem lifesciThomas guillotFlorence portejoieDarren oplandNantes university hospitalChristian albrechts university kielStudy groupBoehringer ingelheimUniversity of kielAmerican society of hematologyLennart lenk department of pediatricsLifesci communicationsUniversity medical center schleswig holstein

Amgen Announces New Data Being Presented At ASH 2021

/PRNewswire/ Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63rd American Society.

United statesHong kongNew zealandUnited arab emiratesPuerto ricoSaudi arabiaMacau generalMegan foxTrish rowlandJakubowiaka semin hematolDavidm reeseKyowa kirin co ltdPregnancy surveillance programDrug administrationYork heart association classBeigene ltd

vimarsana © 2020. All Rights Reserved.